Self‐Cooperative RNA Vaccine Mitigates Dendritic Cell–Mediated Acquired Immune Resistance to Potentiate Cell Therapy for Solid Tumors
Advanced Materials · 2026-08 · 38 (46)
DOI: 10.1002/adma.202518422 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 09.07.2026. Verfasst von Lujia Huang und 14 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Chemical Biology & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, Chin…. Hauptthemen laut MEDLINE: Dendritic Cells, Cancer Vaccines, mRNA Vaccines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality, National Facility for Protein Science in Shanghai.
Abstract (Originalsprache)
Conventional mRNA cancer vaccines are designed to maximize antigen potency but often overlook vaccination‐induced immune resistance. In this study, we identified a negative immune regulatory mechanism, whereby mRNA vaccination induces programmed death‐ligand 1 (PD‐L1) expression in dendritic cells (DCs) through type I interferon (IFN‐I) signaling. Elevated PD‐L1 expression impairs T‐cell priming in lymph nodes through engagement of programmed death receptor 1 (PD‐1) on T lymphocytes. To address this challenge, we developed a self‐cooperative RNA vaccine (SCORV) strategy by co‐delivering antigen‐encoding RNA and small interfering RNA against PD‐L1 (siPD‐L1) within a single lipid nanoparticle (LNP). Through iterative screening of >300 ionizable lipids, we optimized a DC‐targeted LNP formulation with high RNA delivery efficiency and minimal immunotoxicity. SCORV simultaneously suppresses PD‐L1–mediated immune resistance during antigen presentation and enhances T cell priming while alleviating T cell exhaustion. Importantly, SCORV potentiates the tumor reactivity of adoptively transferred tumor‐infiltrating lymphocytes and elicits robust antitumor immunity in murine melanoma and hepatocellular carcinoma models. This work highlights a rational design principle for mRNA vaccines that self‐correct vaccination‐induced immune resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Chemical Biology & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
- University of Chinese Academy of Sciences, Beijing, China.
- School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China.
- School of Pharmacy, Jilin University, Changchun, China.
- The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
- Metis Pharmaceutical, Beijing, China.
ORCID-Profile: Lujia Huang, Haijun Yu
Förderung
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality
- National Facility for Protein Science in Shanghai
Zitieren
APA
Huang, L., Chen, F., Zhou, F., Mao, G., Lan, W., Li, M., Li, S., Gao, J., Cai, Z., Liu, A., Wang, W., Xu, Z., Hou, B., Liu, X., & Yu, H. (2026). Self‐Cooperative RNA Vaccine Mitigates Dendritic Cell–Mediated Acquired Immune Resistance to Potentiate Cell Therapy for Solid Tumors. Advanced Materials, 38(46). https://doi.org/10.1002/adma.202518422
Vancouver
Huang L, Chen F, Zhou F, Mao G, Lan W, Li M, et al. Self‐Cooperative RNA Vaccine Mitigates Dendritic Cell–Mediated Acquired Immune Resistance to Potentiate Cell Therapy for Solid Tumors. Advanced Materials. 2026;38(46). doi:10.1002/adma.202518422
BibTeX
@article{Huang2026,
author = {Huang, Lujia and Chen, Fangmin and Zhou, Feng and Mao, Gujia and Lan, Wenyue and Li, Mengfan and Li, Shiqin and Gao, Jing and Cai, Zhixiong and Liu, Andong and Wang, Wenshou and Xu, Zhiai and Hou, Bo and Liu, Xiaolong and Yu, Haijun},
title = {Self‐Cooperative RNA Vaccine Mitigates Dendritic Cell–Mediated Acquired Immune Resistance to Potentiate Cell Therapy for Solid Tumors},
journal = {Advanced Materials},
year = {2026},
volume = {38},
number = {46},
doi = {10.1002/adma.202518422}
}
EUVIMED